This table contains 267456 series, with data for years 2000 - 2000 (not all combinations necessarily have data for all years). This table contains data described by the following dimensions (not all combinations are available): Geography (199 items: Canada; Newfoundland and Labrador; Health and Community Services St. John's Region; Newfoundland and Labrador (Peer group H); Health and Community Services Eastern Region; Newfoundland and Labrador (Peer group D) ...), Age group (14 items: Total; 12 years and over; 12-19 years; 12-14 years; 15-19 years ...), Sex (3 items: Both sexes; Males; Females ...), Diabetes (4 items: Total population for the variable diabetes; Without diabetes; Diabetes; not stated; With diabetes ...), Characteristics (8 items: Number of persons; High 95% confidence interval - number of persons; Coefficient of variation for number of persons; Low 95% confidence interval - number of persons ...).

Canada CA: Diabetes Prevalence: % of Population Aged 20-79 data was reported at 7.700 % in 2021. This records a decrease from the previous number of 8.400 % for 2011. Canada CA: Diabetes Prevalence: % of Population Aged 20-79 data is updated yearly, averaging 8.050 % from Dec 2011 (Median) to 2021, with 2 observations. The data reached an all-time high of 8.400 % in 2011 and a record low of 7.700 % in 2021. Canada CA: Diabetes Prevalence: % of Population Aged 20-79 data remains active status in CEIC and is reported by World Bank. The data is categorized under Global Database’s Canada – Table CA.World Bank.WDI: Social: Health Statistics. Diabetes prevalence refers to the percentage of people ages 20-79 who have type 1 or type 2 diabetes. It is calculated by adjusting to a standard population age-structure.;International Diabetes Federation, Diabetes Atlas.;Weighted average;

Number and percentage of Canadians aged 20 to 79 with diabetes, prediabetes, as well as diabetes awareness, pharmaceutical treatment and glycemic control among those with diabetes by age group and sex.

This table contains 6720 series, with data for years 1994 - 1998 (not all combinations necessarily have data for all years). This table contains data described by the following dimensions (Not all combinations are available): Geography (5 items: Territories; Northwest Territories; Northwest Territories including Nunavut; Yukon ...), Age group (14 items: Total; 12 years and over;12-14 years;12-19 years;15-19 years ...), Sex (3 items: Both sexes; Females; Males ...), Diabetes (4 items: Total population for the variable diabetes; Without diabetes; With diabetes; Diabetes; not stated ...), Characteristics (8 items: Number of persons; Coefficient of variation for number of persons; High 95% confidence interval - number of persons; Low 95% confidence interval - number of persons ...).

IntroductionPersons with lived experience of homelessness face many challenges in managing diabetes, including purchasing and storing medications, procuring healthy food and accessing healthcare services. Prior studies have found that pharmacy-led interventions for diabetes improved A1C, and lowered blood pressure and cholesterol in general populations. This study evaluated how select pharmacists in Canada have tailored their practices to serve persons with lived experiences of homelessness with diabetes.MethodsWe conducted a qualitative descriptive study using open-ended interviews with inner-city pharmacists in select Canadian municipalities (Calgary, Edmonton, Vancouver, and Ottawa). We used NVivo qualitative data analysis software to facilitate thematic analysis of the data, focusing on how pharmacists contributed to diabetes care for persons with lived experience of homelessness.ResultsThese pharmacists developed diabetes programs after discovering an unmet need in the population. Pharmacists have the unique ability to see patients frequently, allowing tailored education and hands-on assistance with diabetes management. These pharmacists provided extra-ordinary care like financial and housing resources and many of them were uniquely embedded within other services for persons with lived experience of homelessness (i.e. housing and social work supports). Pharmacists reported struggling with balancing optimal medical care for individuals with the financial constraints of running a business.ConclusionPharmacists are vital members of the diabetes care team for persons with lived experience of homelessness. Government policies should support and encourage unique models of care provided by pharmacists to improve diabetes management for this population.

Time series data for the statistic Mortality from CVD, cancer, diabetes or CRD between exact ages 30 and 70 (%) and country Canada. Indicator Definition:Mortality from CVD, cancer, diabetes or CRD is the percent of 30-year-old-people who would die before their 70th birthday from any of cardiovascular disease, cancer, diabetes, or chronic respiratory disease, assuming that s/he would experience current mortality rates at every age and s/he would not die from any other cause of death (e.g., injuries or HIV/AIDS).The indicator "Mortality from CVD, cancer, diabetes or CRD between exact ages 30 and 70 (%)" stands at 9.70 as of 12/31/2021. Regarding the One-Year-Change of the series, the current value constitutes a decrease of -3.00 percent compared to the value the year prior.The 1 year change in percent is -3.00.The 3 year change in percent is -1.02.The 5 year change in percent is -6.73.The 10 year change in percent is -11.01.The Serie's long term average value is 11.51. It's latest available value, on 12/31/2021, is 15.72 percent lower, compared to it's long term average value.The Serie's change in percent from it's minimum value, on 12/31/2019, to it's latest available value, on 12/31/2021, is +1.04%.The Serie's change in percent from it's maximum value, on 12/31/2000, to it's latest available value, on 12/31/2021, is -32.64%.

Rationale:

The accrual of data from the laboratory and from epidemiologic and prevention trials has improved the understanding of the etiology and pathogenesis of type 1 diabetes mellitus (T1DM). Genetic and immunologic factors play a key role in the development of T1DM, and characterization of the early metabolic abnormalities in T1DM is steadily increasing. However, information regarding the natural history of T1DM remains incomplete. The TrialNet Natural History Study of the Development of T1DM (Pathway to Prevention Study) has been designed to clarify this picture, and in so doing, will contribute to the development and implementation of studies aimed at prevention of and early treatment in T1DM.

Purpose:

TrialNet is an international network dedicated to the study, prevention, and early treatment of type 1 diabetes. TrialNet sites are located throughout the United States, Canada, Finland, United Kingdom, Italy, Germany, Sweden, Australia, and New Zealand. TrialNet is dedicated to testing new approaches to the prevention of and early intervention for type 1 diabetes.

The goal of the TrialNet Natural History Study of the Development of Type 1 Diabetes is to enhance our understanding of the demographic, immunologic, and metabolic characteristics of individuals at risk for developing type 1 diabetes.

The Natural History Study will screen relatives of people with type 1 diabetes to identify those at risk for developing the disease. Relatives of people with type 1 diabetes have about a 5% percent chance of being positive for the antibodies associated with diabetes. TrialNet will identify adults and children at risk for developing diabetes by testing for the presence of these antibodies in the blood. A positive antibody test is an early indication that damage to insulin-secreting cells may have begun. If this test is positive, additional testing will be offered to determine the likelihood that a person may develop diabetes. Individuals with antibodies will be offered the opportunity for further testing to determine their risk of developing diabetes over the next 5 years and to receive close monitoring for the development of diabetes.

This table contains 14784 series, with data for years 1994 - 1998 (not all combinations necessarily have data for all years). This table contains data described by the following dimensions (not all combinations are available): Geography (11 items: Canada; Newfoundland and Labrador; Prince Edward Island; Nova Scotia ...), Age group (14 items: Total; 12 years and over; 15-19 years; 12-19 years; 12-14 years ...), Sex (3 items: Both sexes; Males; Females ...), Diabetes (4 items: Total population for the variable diabetes ;With diabetes; Without diabetes; Diabetes; not stated ...), Characteristics (8 items: Number of persons; Low 95% confidence interval - number of persons; High 95% confidence interval - number of persons; Coefficient of variation for number of persons ...).

BackgroundA pervasive and persistent finding is the health disadvantage experienced by those in food insecure households. While clear associations have been identified between food insecurity and diabetes risk factors, less is known about the relationship between food insecurity and incident type 2 diabetes. The objective of this study is to investigate the association between household food insecurity and the future development of type 2 diabetes.MethodsWe used data from Ontario adult respondents to the 2004 Canadian Community Health Survey, linked to health administrative data (n = 4,739). Food insecurity was assessed with the Household Food Security Survey Module and incident type 2 diabetes cases were identified by the Ontario Diabetes Database. Multivariable adjusted Cox proportional hazards models were used to estimate hazard ratios (HRs) and 95% confidence intervals (CIs) for type 2 diabetes as a function of food insecurity.ResultsCanadians in food insecure households had more than 2 times the risk of developing type 2 diabetes compared to those in food secure households [HR = 2.40, 95% CI = 1.17–4.94]. Additional adjustment for BMI attenuated the association between food insecurity and type 2 diabetes [HR = 2.08, 95% CI = 0.99, 4.36].ConclusionsOur findings indicate that food insecurity is independently associated with increased diabetes risk, even after adjustment for a broad set of measured confounders. Examining diabetes risk from a broader perspective, including a comprehensive understanding of socioeconomic and biological pathways is paramount for informing policies and interventions aimed at mitigating the future burden of type 2 diabetes.

The North American self-monitoring blood glucose (SMBG) market, valued at $8.10 billion in 2025, is projected to experience robust growth, driven by the increasing prevalence of diabetes and the rising geriatric population. The market's Compound Annual Growth Rate (CAGR) of 6.98% from 2019 to 2025 indicates a consistent upward trend. Key drivers include advancements in SMBG device technology, such as the development of more accurate, user-friendly, and cost-effective glucometers and lancets. Furthermore, increased awareness of diabetes management and the growing adoption of remote patient monitoring contribute significantly to market expansion. While data for individual countries within North America (United States, Canada, and Rest of North America) are not provided, we can infer that the United States likely holds the largest market share given its substantial population and higher prevalence of diabetes compared to Canada. The Rest of North America segment will likely exhibit moderate growth, reflecting the combined market dynamics of smaller countries in the region. Market restraints may include the potential for reimbursement challenges and the emergence of alternative glucose monitoring technologies, such as continuous glucose monitors (CGMs). However, the overall market outlook remains positive, fueled by the persistent need for effective diabetes management. Major players like Abbott, Roche, and LifeScan continue to innovate and compete, further shaping the market landscape. The forecast period (2025-2033) promises continued growth driven by technological advancements and an aging population requiring consistent blood glucose monitoring. The competitive landscape is characterized by established players like Abbott, Roche, and LifeScan, along with other significant contributors like Arkray, Ascensia, and Agamatrix. These companies are continuously striving for innovation to maintain their market share. This involves introducing technologically advanced devices, improving user experience, and developing more comprehensive diabetes management solutions. The increasing demand for accurate, convenient, and affordable SMBG devices, coupled with the growing awareness of diabetes self-management, will drive further market expansion. The incorporation of data analytics and connectivity features in SMBG devices also plays a crucial role in fostering better diabetes management and patient outcomes, thereby bolstering the market's growth trajectory. The focus on improving patient outcomes and reducing healthcare costs will likely shape future market developments, attracting further investments and technological advancements within the sector. Recent developments include: May 2023: LifeScan announced positive data from a study of real-world evidence supporting its Bluetooth-connected blood glucose meter. Evidence from more than 55,000 people with diabetes demonstrated sustained improvements in readings in range. The analysis focuses on changes over 180 days. LifeScan published results in the peer-reviewed journal Diabetes Therapy. The company’s OneTouch Bluetooth-connected blood glucose meter and mobile diabetes app provide simplicity, accuracy, and trust., January 2023: LifeScan announced that the peer-reviewed Journal of Diabetes Science and Technology published Improved Glycemic Control Using a Bluetooth-Connected Blood Glucose Meter and a Mobile Diabetes App: Real-World Evidence from Over 144,000 People With Diabetes, detailing results from a retrospective analysis of real-world data from over 144,000 people with diabetes is one of the largest combined blood glucose meter and mobile diabetes app datasets ever published.. Notable trends are: Blood Glucose Test Strips Held the Largest Market Share in Current Year.

BackgroundHealthy eating during pregnancy has favorable effects on glycemic control and is associated with a lower risk of gestational diabetes mellitus (GDM). According to Diabetes Canada, there is a need for an effective and acceptable intervention that could improve glucose homeostasis and support pregnant individuals at risk for GDM.AimsThis unicentric randomized controlled trial (RCT) aims to evaluate the effects of a nutritional intervention initiated early in pregnancy, on glucose homeostasis in 150 pregnant individuals at risk for GDM, compared to usual care.MethodsPopulation: 150 pregnant individuals ≥18 years old, at ≤14 weeks of pregnancy, and presenting ≥1 risk factor for GDM according to Diabetes Canada guidelines. Intervention: The nutritional intervention initiated in the first trimester is based on the health behavior change theory during pregnancy and on Canada’s Food Guide recommendations. It includes (1) four individual counseling sessions with a registered dietitian using motivational interviewing (12, 18, 24, and 30 weeks), with post-interview phone call follow-ups, aiming to develop and achieve S.M.A.R.T. nutritional objectives (specific, measurable, attainable, relevant, and time-bound); (2) 10 informative video clips on healthy eating during pregnancy developed by our team and based on national guidelines, and (3) a virtual support community via a Facebook group. Control: Usual prenatal care. Protocol: This RCT includes three on-site visits (10–14, 24–26, and 34–36 weeks) during which a 2-h oral glucose tolerance test is done and blood samples are taken. At each trimester and 3 months postpartum, participants complete web-based questionnaires, including three validated 24-h dietary recalls to assess their diet quality using the Healthy Eating Food Index 2019. Primary outcome: Difference in the change in fasting blood glucose (from the first to the third trimester) between groups. This study has been approved by the Ethics Committee of the Centre de recherche du CHU de Québec-Université Laval.DiscussionThis RCT will determine whether a nutritional intervention initiated early in pregnancy can improve glucose homeostasis in individuals at risk for GDM and inform Canadian stakeholders on improving care trajectories and policies for pregnant individuals at risk for GDM.Clinical trial registrationhttps://clinicaltrials.gov/study/NCT05299502, NCT05299502

BackgroundPrinted educational materials for clinician education are one of the most commonly used approaches for quality improvement. The objective of this pragmatic cluster randomized trial was to evaluate the effectiveness of an educational toolkit focusing on cardiovascular disease screening and risk reduction in people with diabetes.Methods and FindingsAll 933,789 people aged ≥40 years with diagnosed diabetes in Ontario, Canada were studied using population-level administrative databases, with additional clinical outcome data collected from a random sample of 1,592 high risk patients. Family practices were randomly assigned to receive the educational toolkit in June 2009 (intervention group) or May 2010 (control group). The primary outcome in the administrative data study, death or non-fatal myocardial infarction, occurred in 11,736 (2.5%) patients in the intervention group and 11,536 (2.5%) in the control group (p = 0.77). The primary outcome in the clinical data study, use of a statin, occurred in 700 (88.1%) patients in the intervention group and 725 (90.1%) in the control group (p = 0.26). Pre-specified secondary outcomes, including other clinical events, processes of care, and measures of risk factor control, were also not improved by the intervention. A limitation is the high baseline rate of statin prescribing in this population.ConclusionsThe educational toolkit did not improve quality of care or cardiovascular outcomes in a population with diabetes. Despite being relatively easy and inexpensive to implement, printed educational materials were not effective. The study highlights the need for a rigorous and scientifically based approach to the development, dissemination, and evaluation of quality improvement interventions.Trial Registrationhttp://www.ClinicalTrials.gov NCT01411865 and NCT01026688Please see later in the article for the Editors' Summary

This figure provides the age-standardized inpatient separation rates per 100,000 population for selected conditions. An inpatient separation from a health care facility occurs anytime a patient (or resident) leaves because of death, discharge, sign-out against medical advice or transfer. The number of separations is the most commonly used measure of the utilization of hospital services. Separations, rather than admissions, are used because hospital abstracts for inpatient care are based on information gathered at the time of discharge. The selected conditions are Asthma, Diabetes, Influenza, Ischemic Heart Diseases, Mental and Behavioural Disorders due to Psychoactive Substance Use, Pneumonia, Pulmonary Heart and Pulmonary Circulation Diseases. Age standardization is a technique applied to make rates comparable across groups with different age distributions. A simple rate is defined as the number of people with a particular condition divided by the whole population. An age-standardized rate is defined as the number of people with a condition divided by the population within each age group. Standardizing (adjusting) the rate across age groups allows a more accurate comparison between populations that have different age structures. Age standardization is typically done when comparing rates across time periods, different geographic areas, and or population sub-groups (e.g. ethnic group). This indicator dataset contains information at both Local Geographic Area (for example, Lacombe, Red Deer, Calgary West Bow, etc.) and Alberta levels. Local geographic area refers to 132 geographic areas created by Alberta Health (AH) and Alberta Health Services (AHS) based on census boundaries. This table is the part of "Alberta Health Primary Health Care - Community Profiles" report published March 2019.